Parker Singleton

Come join an amazing team where you're guaranteed to set yourself up for future success!

💊 🍸 Risk for substance use disorder (SUD) rises in adolescence. Family history and biological sex play major roles in a person's level of SUD risk. New evidence suggests neural markers of SUD may exist before substance use starts - yet how these markers differ across sexes is not understood.

🧠I am excited to announce that our manuscript introducing a new data resource – PennLEAD (Penn Longitudinal Executive functioning in Adolescent Development) – is now available on bioRxiv. Below are some details highlighting our data resource🧵funded by NIMH R01MH113550
www.biorxiv.org/content/10.1...

Diffusion MRI Processing in the HEALthy Brain and Child Development Study: Innovations and Applications The landmark ongoing HEALthy Brain and Cognitive Development (HBCD) study will longitudinally chart brain development in a large sample (projected n=7,200) of infants through age 10 years with multimo...

After years of development and testing, we are happy to present our work in "Diffusion MRI Processing in the HEALthy Brain and Child Development Study: Innovations and Applications"! www.biorxiv.org/content/10.1.... A thread:

Strongest data yet suggesting that repeated MDMA use causes deficits in declarative memory (e.g., memory for new information, words, etc). #psychedelicscience #MDMA

10.1093/brain/awaf391

I thought about busting the PS out of the attic recently just for Spyro and Crash Bandicoot

Hot off the press!

Psychedelic 5-HT2A receptor agonism alters neurovascular coupling and differentially affects neuronal and hemodynamic measures of brain function Nature Neuroscience - Padawer-Curry et al. show that the hallucinogenic 5-HT2A receptor agonist DOI alters neurovascular coupling in mice, with implications for the interpretation of human fMRI...

🚨 New science alert! Our cross-species study, now in Nature Neuroscience, demonstrates psychedelics distort how we should interpret functional brain imaging.
👇🧵

nature.com/articles/s41...
#Neuroscience #Psychedelics #BrainImaging

If you agree to review a paper, you should send it in on time. You're holding a spot and slowing up the whole process if you don't.

I just saw someone use the abbreviation “AI;DR” and I’ll be laughing for a while.

Amazing stuff here from @goliashf.bsky.social and the RBC team! Harmonized and curated imaging and phenotype data from over 6,000 youth easily accessible without any DUA. Check it out.

New preprint from stellar IRTG PhD student Amelie Rauland + team on white matter bundle reconstruction! Shows that WM bundles can be reliably extracted from simple 32-direction dMRI & features predict cognition - huge potential for legacy and clinical data. Thread 👇

www.biorxiv.org/cgi/content/...

my linkedin feed has become filled with psychedelic memes and I'm connected with an OG acid kingpin.

I'm near certain sLFOs are big for psychedelics.

Since July 21st, we have a good reason to celebrate the summa cum laude Defense of the newly minted Dr. Hettwer who received her PhD from @hhu.de under the supervision of Prof. Simon Eickhoff @sbe.bsky.social with strongest support of Dr. Sofie Valk! Congratulations Meike!!!🥂👏🏻🥁🎊

"Spatiotemporal asymmetries on brain energy landscape uncover system entrapment related to depression severity"

www.researchsquare.com/article/rs-7...

✨ New paper ✨ in JAMA Pediatrics! We discuss how understanding the timing ⏰ of stressful events relative to neurodevelopment can help us better identify risk factors (looking backward) and predict future psychopathology (looking forward) at the individual level
#neuroskyence #devpsych #PsychSciSky

Is it possible to manipulate a high-level visual property while holding ~all low-level visual properties constant?

“No!”, you say.

Allow @talboger.bsky.social to show you otherwise! Now
in press @currentbiology.bsky.social

🐇🐘

Thanks Parker!

Just delighted to see this out in the world !! This is the first installment of SYPRES -- our living meta-analysis + open data resource focused on psychedelics. Led by the incomparable @parkersingleton.bsky.social and @bsevchik.bsky.social. Check it out + and give us your feedback!!!

Analiese Lahey, @pimcuijpers.bsky.social, @mathiasharrer.bsky.social, @mntj21.bsky.social, Sandeep Nayak, Eric Strain, @vandyatvandy.bsky.social, Bob Dworkin, @jcobbscott.bsky.social. @ted-satterthwaite.bsky.social, @pennlinc.bsky.social

All of this and more can be easily accessed through sypres.io

Team effort with co-first author (!!!) @bsevchik.bsky.social and the rest of the SYPRES and Metapsy team who made this happen!

screenshot of the dashboard home page

In partnership with metapsy.org we built an interactive dashboard for exploring the data. Users can:
• Filter studies by characteristics
• Test different analysis parameters
• Test moderators
• Download figures and reports

Dashboard: metapsy.org/sypres/psilo...

screenshot of the GitHub repository readme for the database

Our database includes 200+ effect sizes, encompassing all depression outcomes and timepoints reported by arm in each of the 12 RCTs included. This database can be downloaded from our website (sypres.io) or imported directly into R environments using the metapsyData package from metapsy.org

Forest plot of effect sizes.

Here, psilocybin showed a greater reduction in depression scores compared to control conditions, with a pooled Hedges’ g = -0.91 (k = 9; p = 0.0013, I2 = 58.1%, n = 501). But important caveats—small studies, blinding challenges, risk of bias, and design heterogeneity, which we discuss in the paper.

screenshot of the psilocybin for depression section on sypres.io

sypres.io is our new initiative featuring:
📊 Regularly updated meta-analyses
🔍 User-guided sensitivity and moderation analysis
🕵️ Transparent study quality & risk-of-bias assessments
⚙️ Open code & data

Image of the Gartner hype cycle

Psychedelic science has experienced the benefits and drawbacks of hype. However, new results are rarely contextualized in the historical body of evidence in an accessible manner. We need more robust, living, evidence synthesis that is visible and accessible to all stakeholders.

SYPRES (Synthesis of Psychedelic Research Studies) logo

🍄 Our new living systematic review and meta-analysis on psilocybin for depression is out. Here's what we found and the open science infrastructure we built to support it 🧪🧵
www.medrxiv.org/content/10.1...

@audreycluo.bsky.social has had one of the most impressive graduate careers I've ever seen. Kudos!!!!

Somehow we got almost all the students and postdocs in one photo!!

Until next time #GRCPsychedelics 🫡